Akero Therapeutics, Inc. (AKRO) Research

Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing cardio-metabolic disorders, with a specific focus on nonalcoholic steatohepatitis (NASH). Its primary objective is the creation of therapeutic agents aimed at re-establishing metabolic equilibrium and enhancing overall well-being. The company's flagship investigational drug is efruxifermin (EFX), a synthetic analog of fibroblast growth factor 21. EFX is designed to shield cells from stress and modulate the systemic metabolism of fats, carbohydrates, and proteins throughout the body. This promising compound is currently undergoing evaluation in a Phase 2a clinical investigation, known as the BALANCED study, for individuals diagnosed with biopsy-confirmed NASH. Originally established as Pippin Pharmaceuticals, Inc., the organization rebranded as Akero Therapeutics, Inc. in May 2018. Founded in 2017, Akero Therapeutics maintains its corporate headquarters in South San Francisco, California.

Market snapshot

Symbol
AKRO
Price
$54.65
Day change
0.00%
Market cap
$4.5B
P/E ratio
-15.31x
52-week range
21.34-58.4
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$48.40

Peer companies

  • ACADIA Pharmaceuticals Inc. (ACAD)
  • Arcellx, Inc. (ACLX)
  • Centessa Pharmaceuticals plc (CNTA)
  • Crinetics Pharmaceuticals, Inc. (CRNX)
  • Immunovant, Inc. (IMVT)
  • Kymera Therapeutics, Inc. (KYMR)
  • NewAmsterdam Pharma Company N.V. (NAMS)
  • Praxis Precision Medicines, Inc. (PRAX)

Recent insider activity

  • Heyman Tomas J. — D-Return (13000 shares) on 2025-12-09
  • Heyman Tomas J. — D-Return (26000 shares) on 2025-12-09
  • Heyman Tomas J. — D-Return (15000 shares) on 2025-12-09
  • Heyman Tomas J. — D-Return (15000 shares) on 2025-12-09
  • Heyman Tomas J. — D-Return (9398 shares) on 2025-12-09

Open Akero Therapeutics, Inc. (AKRO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.